Shiwei Tu

机构：Jiangsu Hengrui Medicine (China)

发表论文 7 篇 · 总被引 93 次 · h-index 3

代表论文

• Gambogenic acid inhibits fibroblast growth factor receptor signaling pathway in erlotinib-resistant non-small-cell lung cancer and suppresses patient-derived xenograft growth (2018 · Cell Death and Disease · 被引 48)
• Ubiquitin-conjugating enzyme UbcH10 promotes gastric cancer growth and is a potential biomarker for gastric cancer (2016 · Oncology Reports · 被引 25)
• SHR-A1811, a novel anti-HER2 antibody–drug conjugate with optimal drug-to-antibody ratio, efficient tumor killing potency, and favorable safety profiles (2025 · PLoS ONE · 被引 17)
• SHR-A1811, a novel anti-HER2 antibody–drug conjugate with optimal drug-to-antibody ratio, superior bystander killing effect and favorable safety profiles (2023 · Research Square · 被引 2)
• Temporal heterogeneity in antibody–drug conjugate targets in paired primary and recurrent ovarian cancer samples (2026 · International Journal of Gynecological Cancer · 被引 1)
• Abstract 4929: UbcH10 may represent a potential marker of gastric carcinoma (2016 · Cancer Research)